Diagnosis and management of acute respiratory distress syndrome

• Acute respiratory distress syndrome (ARDS) can arise from a variety of causes, and manifests clinically as acute hypoxemic respiratory failure, characterized by acute, diffuse, inflammatory lung injury that leads to increased alveolar capillary permeability and development of nonhydrostatic pulmonary edema.

• Clinical diagnosis of ARDS is made on the basis of the Berlin definition, with severity of the disease and prognosis for survival based on the degree of hypoxemia.

• The mainstay of therapy in ARDS is invasive mechanical ventilation using a lung-protective strategy, but other adjunctive therapies have been trialed with various degrees of efficacy.

• Clinically and radiographically, severe COVID-19 appears similar to ARDS; management of severe COVID-19 should focus on the principles of ARDS therapy, with added insight from recent high-quality randomized trials.

Acute respiratory distress syndrome (ARDS) is a life-threatening form of respiratory failure, characterized by acute, diffuse, inflammatory lung injury,1 that results in increased alveolar capillary permeability and the development of nonhydrostatic pulmonary edema. Clinically, ARDS manifests as marked hypoxemia and respiratory distress; patients often progress to respiratory failure that requires invasive mechanical ventilation in the intensive care unit (ICU). The risk of death is high. A variety of conditions can cause ARDS, including pneumonia, extrapulmonary sepsis or septic shock, trauma and pancreatitis. Despite consensus guidelines on the management of ARDS,2^–4 substantial worldwide variation in management continues, and gaps in evidence remain, including in the context of ARDS associated with COVID-19.5^,6 We provide an update on the diagnosis and management of ARDS for the generalist clinician, based on recent clinical practice guidelines, systematic reviews and original studies (Box 1).

What is ARDS and how is it diagnosed?

Acute respiratory distress syndrome was originally described in 1967 as a clinical syndrome characterized by acute onset of tachypnea, hypoxemia and loss of lung compliance after a variety of stimuli; the original description also noted that ARDS was not responsive to usual and ordinary methods of respiratory therapy.7 The hallmark of this syndrome is diffuse lung inflammation, resulting in development of pulmonary edema. Morphologically, the acute phase of ARDS is characterized by diffuse alveolar damage.1 Formal diagnostic criteria for ARDS were not widely accepted until the 1994 American–European Consensus Conference (AECC).8 The AECC criteria include the acute onset of hypoxemia, the presence of noncardiogenic, bilateral infiltrates on chest radiographs and the absence of left atrial hypertension. The presence of hypoxemia was quantified using the ratio of partial pressure of arterial oxygen and the fraction of inspired oxygen (Pao₂/FiO₂), with a Pao₂/FiO₂ < 200 mm Hg required for diagnosis of ARDS. The AECC definition was limited by several factors, namely the lack of an explicit time of onset, potential interobserver variability of the chest radiograph and the requirement for pulmonary artery catheterization to rule out left atrial hypertension.1

In 2012, the clinical criteria for diagnosis of ARDS were refined to address these limitations, resulting in the Berlin definition.9 For diagnosis of ARDS, the patient must have new or worsening symptoms within 1 week of a known clinical insult; bilateral opacities observable on anteroposterior chest radiographs that are not due to effusions, nodules or lobar or lung collapse; and hypoxemia, defined by a Pao₂/FiO₂ < 300 mm Hg and a minimum positive end-expiratory pressure ≥ 5 cm H₂O, that is not fully explained by cardiac failure or fluid overload (Figure 1).

• Download figure
• Open in new tab
• Download powerpoint

Figure 1:

Anteroposterior chest radiograph showing bilateral pulmonary infiltrates, consist with acute respiratory distress syndrome.

The Berlin definition also identified mutually exclusive categories of ARDS severity based on the degree of hypoxemia, including mild (Pao₂/FiO₂ 200–300 mm Hg), moderate (Pao₂/FiO₂ 100–200 mm Hg) and severe (Pao₂/FiO₂ < 100 mm Hg) ARDS. These categories correspond to prognosis, with higher severity associated with increased mortality rates in the data sets used for derivation of the criteria.9^,10

What is the burden of ARDS?

In the LUNG SAFE prospective cohort study, the Berlin definition was used to identify patients with ARDS from 459 ICUs in 50 countries across 5 continents.5 In this study, ARDS accounted for 10.4% of all ICU admissions and 23.4% of patients requiring mechanical ventilation. The most common causes of ARDS were pneumonia, extrapulmonary sepsis, aspiration and trauma. The median duration of mechanical ventilation of patients with ARDS was 8 (interquartile range 4–16) days. The number of deaths was substantial, with 39.6% of patients dying in hospital, and increased with severity of ARDS (34.9%, 40.3% and 46.1% of patients with mild, moderate and severe disease dying in hospital, respectively). Administrative data show that, although mortality rates from ARDS have decreased overall in the last 2 decades, racial and sex disparities still exist and survivors have substantial morbidity.11 Survivors of ARDS show severe muscle weakness and fatigue that persist up to 5 years after hospital discharge, which result in impaired functional ability and reduced exercise tolerance.12^, 13 Furthermore, survivors describe important psychological, cognitive and economic sequelae associated with ARDS.13

What are the mainstays of treatment?

The LUNG SAFE study found variations in the use of evidence-based treatments for ARDS across centres in Europe.5 Few therapies are based on strong evidence, but over the past 2 decades, important advances have been made in the management of the syndrome, particularly related to ventilation. These have subsequently been incorporated into clinical practice guidelines.2^–4 Figure 2 summarizes a suggested approach to the management of patients with ARDS.

• Download figure
• Open in new tab
• Download powerpoint

Figure 2:

Suggested treatment algorithm showing risk stratification and tiered approach to therapy for patients with acute respiratory distress syndrome (ARDS). Note: HFNC = high-flow nasal cannula, HFOV = high-frequency oscillatory ventilation, PEEP = positive end-expiratory pressure, PBW = predicted body weight, VV-ECMO = venovenous extracorporeal membrane oxygenation.

Is ARDS that is associated with COVID-19 a distinct entity?

The COVID-19 pandemic brought the management of ARDS into the spotlight in 2020. Development of ARDS secondary to severe COVID-19 was (and is) common, and it was unclear whether COVID-19–associated ARDS was a distinct entity from other forms of ARDS, and whether a different management strategy was necessary.34 Consideration of alternate strategies for COVID-19–associated ARDS arose from early reports.35 Two distinct ARDS phenotypes were described among patients with COVID-19: type H, marked by high pulmonary elastance, high ventilation/perfusion ratio, high lung weight, and high alveolar recruitability (consistent with typical severe ARDS), and the more novel type L, marked by low values for the same variables.36 Some experts suggested that most patients with COVID-19–associated ARDS would initially present with type L characteristics, with only some transitioning to type H, and asserted that clinicians should therefore consider early intubation in patients with type L ARDS, further suggesting that these patients might tolerate higher tidal volumes without risk of ventilator-induced lung injury.35^,36

However, accumulating evidence does not support this characterization of COVID-19–associated ARDS.34 First, patients without COVID-19 who meet the Berlin definition of ARDS are known to have variable degrees of pulmonary elastance and recruitability,5 and the idea of distinct phenotypes among patients with ARDS has been previously proposed and shown in a more rigorous fashion.37 Despite this, identification of phenotypes has not yet translated into differences in the management of ARDS by clinicians.34 Second, further reports evaluating the lung mechanics of patients with COVID-19–associated ARDS show that these patients are similar to conventional patients with ARDS.38 In fact, the proposed phenotypes of COVID-19–associated ARDS likely represent the natural evolution of ARDS. As such, using existing evidence-based therapies that protect the lungs and avoid iatrogenic injury likely represents the best way forward.39 Although future evidence may change management approaches, no convincing evidence currently suggests that COVID-19–associated ARDS is a distinct entity, or that an alternative treatment strategy is necessary, particularly with regard to ventilation. In fact, therapies that are commonly used for the treatment of ARDS may be effective for COVID-19–associated ARDS.

Patients with COVID-19 may benefit from noninvasive ventilation (namely high-flow nasal cannula) and prone positioning while awake, both of which appear to improve hypoxemia and avoid intubation,40^,41 and are the subject of ongoing randomized trials. Most notable is the use of steroids (primarily dexamethasone), which has been shown to reduce mortality rates among mechanically ventilated patients with COVID-19.42^,43 Although the use of tocilizumab, a monoclonal antibody, may be effective in reducing mechanical ventilation and death in hospitalized patients with COVID-19,44^,45 the use of therapeutic anticoagulation among patients with severe COVID-19 does not appear to be beneficial.46 Finally, many patients with ARDS, whether associated with COVID-19 or not, may require a lengthy duration of mechanical ventilation. Therefore, tracheostomy may become necessary, and clinicians should adhere to recommendations related to safety, conduct and management of tracheostomy.47

What uncertainties remain regarding the management of ARDS?

Important areas for future study in ARDS therapy are summarized in Figure 3. Although lung-protective ventilation with traditional pressure- or volume-targeted modes have been the cornerstone of ARDS management, novel ventilatory modes may also be efficacious. First, airway pressure release ventilation (APRV) is a pressure-control mode of ventilation that may minimize ventilator-induced lung injury. This approach periodically deflates the lungs (“release”) from a higher level of continuous positive airway pressure, rather than trying to inflate the lung to ideal lung volumes by overcoming poor compliance with higher pressures. Theoretically, by maintaining continuous pressures at moderate levels, APRV may reduce ventilator-induced lung injury. However, a recent randomized trial found that APRV had no impact on mortality rates in ARDS, although it was associated with reduced duration of mechanical ventilation and ICU length of stay, compared with volume-controlled, lung-protective ventilation.48 Further clinical trials on the efficacy of APRV are needed.

• Download figure
• Open in new tab
• Download powerpoint

Figure 3:

Future directions in the management of acute respiratory distress syndrome (ARDS).

The potential for exacerbation of lung injury through patient self-inflicted lung injury (P-SILI) is another interesting area of study. Although supported by a strong physiologic rationale, there is a paucity of human data to understand P-SILI.49 Theoretically, the risk of P-SILI may be mitigated by controlling respiratory drive and effort through neuromuscular blockade, sedation or extracorporeal life support. At present, there is limited evidence that controlling respiratory effort and drive is associated with improved outcomes in patients with ARDS.50

Finally, although VV-ECMO is beneficial for patients with severe ARDS for whom conventional management is failing, another emerging form of extracorporeal life support that may be valuable in the management of moderate-to-severe ARDS is extracorporeal carbon dioxide removal.51 For patients receiving mechanical ventilation with very low tidal volumes, there is a risk of hypoventilation and resultant hypercapnea and acidosis. Extracorporeal carbon dioxide removal can facilitate very low tidal volumes by providing an extracorporeal method to reduce carbon dioxide. Unlike VV-ECMO, this approach uses smaller catheters, though there are important associated risks, mainly related to bleeding.52 Extracorporeal carbon dioxide removal may be considered for patients with moderate ARDS and may prevent progression to severe disease; trials to study its efficacy are ongoing.

Conclusion

Acute respiratory distress syndrome causes respiratory failure that most commonly occurs secondary to pneumonia, sepsis, trauma or aspiration. Increasing severity of hypoxemia in ARDS is associated with high risk of mortality. Management of ARDS is largely focused on supportive management, lung-protective ventilation and minimizing iatrogenic forms of lung injury, with extracorporeal life support as an option for patients who continue to deteriorate despite these supportive therapies. Acute respiratory distress syndrome that is associated with COVID-19 does not appear to be distinct from the conventional syndrome, and existing therapies should remain the mainstay of treatment.